Europe Psychedelic Drugs Market - Industry Trends and Forecast to 2029

Europe psychedelic drugs market is projected to register a substantial CAGR of 12.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029.

Market Segmentation:

 
Europe Psychedelic Drugs Market, By Source (Synthetic & Natural), Type (Empathogens, Dissociatives & Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin & Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder & Others), Route of Administration (Oral, Inhalation & Injectable), End User (Hospitals, Specialty Clinics, Homecare & Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy & Online Pharmacy), Country (Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Belgium, Lithuania & Rest of Europe) - Market Trends and Forecast to 2029

Some of the major factors contributing to the growth of the Europe psychedelic drugs market are:

• Growing acceptance of psychedelic drugs for treating depression

• Increasing prevalence of depression and mental disorders

Market Players:

The key market players for Europe psychedelic drugs market are listed below:

• Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.)
• Hikma Pharmaceuticals PLC
• COMPASS
• Verrian 
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Jazz Pharmaceuticals, Inc.
• Avadel
• Celon Pharma S.A.
• NeuroRx, Inc.
• Mind Medicine, Inc.